PNAS: In the late 1980s you identified VAMP (vesicle associated membrane protein), one of the first known protein components of the synaptic machinery, in a marine ray. That discovery later revealed the mechanics of neurotransmission. Can you briefly describe how you discovered the protein?
Scheller: We had made a cDNA library from the electromotor neurons of the Pacific electric ray (Torpedo californica) to isolate cDNAs encoding another protein called Agrin, which is involved in the development and maintenance of the neuromuscular junction. And others had developed antibodies against proteins in synaptic vesicles. I thought I would use some of those antibodies to isolate DNA encoding proteins in the synaptic machinery using the cDNA expression library, and then use molecular techniques to unravel the functions of those proteins. We did the screen, and the first clone we pulled out turned out to encode VAMP, which has since become the first known vesicle-SNARE.
PNAS: Since the uncovering of the synaptic fusion complex, our understanding of synaptic transmission has grown enormously. But have any of the proteins in the fusion complex or their interacting partners been directly implicated in neurobiological disorders?
Scheller: The major proteins in the complex have not really been implicated in any neurobiological disorders, but their functions are so fundamental that their knockouts are simply not viable. Tinkering with the proteins of the fusion machinery would not result in a viable brain.
PNAS: After nearly two decades at Stanford, where you carried out most of the neurotransmission-related cloning and characterization, you moved to Genentech in 2001. What prompted the move?
Scheller: Most of the synaptic transmission-related work was carried out at Stanford, and it was a nice set of discoveries, but I thought that it was time to do something else. The question then was what. I considered moving to other universities, but that didn't really make sense because my wife and I were both happy at Stanford. When the opportunity at Genentech came up, I thought it would be a way to apply the biological intuition I had developed over 30 years to medical problems. I was drawn to the challenge of the learning experience.
PNAS: At Genentech, you oversee research and early development of drugs. Can you give our readers a couple of examples of recent notable successes and failures?
Scheller: Early-stage drug development is a combination of success and failure, and it's often humbling to test molecules in people. We recently received approval for Erivedge, an inhibitor of the Hedgehog pathway, which is mutated in 90% of basal cell carcinoma, a skin cancer often treated by simply removing the lesions, unless the lesions grow and become metastatic. The approval of this molecule in the United States, and more recently in Europe, to treat the advanced forms of this cancer, is a triumph for Genentech and the result of years of work by a team led by Frederic de Sauvage. On the flip side, we had a program for an antibody against the oxidized form of LDL [low density lipoprotein, which carries cholesterol in blood], which we thought might underlie some of the inflammation in plaques related to heart disease. So we did a phase 2 trial of the antibody, but it failed to demonstrate any reduction in inflammation or plaque size. We halted the trial. Clinical trials often serve as a reminder that textbook versions of cellular pathways might be oversimplifications of biology.
PNAS: Among industry players, Genentech has often been lauded for its starkly academic approach to drug development, particularly with regard to scientifically driven decision-making and willingness to back risky projects. In your view what is behind this characterization?
Scheller: I think it's the company's history: following the basic science, publishing highquality research more prolifically than many other companies, and hosting a postdoctoral research program. Our postdocs are encouraged to publish great research and to go out and get jobs in industry and academia. They don't work only on translational projects but on whatever is scientifically interesting to them. Genentech has always tried to put scientific opportunities and unmet medical need ahead of commercial interests. That's how we make decisions on what projects to pursue and that's part of the reason for our success.
PNAS: From your vantage point at Genentech, what are some of the most promising therapeutic areas to watch for?
Scheller: I'm particularly excited about oncology because of the huge amount of information gained from the cancer genome. We now know most of the major mutated oncogenes that drive tumor formation and proliferation. Now we just have to develop terrific therapeutics. Alzheimer's disease, Crohn disease, asthma, and infectious diseases (such as drug-resistant Staphylococcus, flu, and cytomegalovirus) are some of the other areas on our agenda.
